. 2014 Jul 11;9(7):e101562. doi: 10.1371/journal.pone.0101562

Table 2. Estimation of the relative hazard of death for patients with colorectal cancer, lung cancer and malignant melanoma, diagnosed 1997–2006.

	Crude HR (95% CI)	Adjusted HR^1,2 (95%CI)
Colorectal Cancer
All patients (M/F)	1.09 (1.02 to 1.17)	1.20 (1.12 to 1.29)
	p = 0.016	p<0.001
All patients, excluding those whose death is recorded as day of diagnosis³	1.12 (1.05 to 1.20)	1.21 (1.13 to 1.30)
	P = 0.001	p<0.001
Patients with fatalities (died during follow up period)	0.86 (0.80 to 0.92)	0.88 (0.83 to 0.95)
	p<0.001	p = 0.0004
Lung Cancer
All patients	1.24 (1.16 to 1.33)	1.24 (1.16 to 1.33)
	p<0.001	p<0.001
All patients, excluding those whose death is recorded as day of diagnosis⁴	1.23 (1.15 to 1.31)	1.22 (1.15 to 1.30)
	p<0.001	p<0.001
Patients with fatalities (died in during follow up period)	1.07 (1.01 to 1.14)	1.08 (1.01 to 1.15)
	p = 0.0271	p = 0.0207
Malignant Melanoma
All patients	1.89 (1.64 to 2.18)	1.73 (1.51 to 1.99)
	p<0.001	p<0.001
All patients, excluding those whose death is recorded as day of diagnosis⁵	2.19 (1.81 to 2.65)	1.93 (1.62 to 2.31)
	p<0.001	p<0.001
Patients with fatalities (died in during follow up period)	1.04 (0.90 to 1.19)	1.04 (0.91 to 1.20)
	p = 0.5999	p = 0.5325

^1.

adjusted for age (as continuous variable) and socioeconomic status.

^2.

including a generalized random intercept term for each patient to account for observed overdispersion.

^3.

210 (3.2%) of men and 210 (3.71%) of women, p = 0.14.

^4.

553 (8.4%) of men and 367 (8.2%) of women, p = 0.73.

^5.

11 (0.6%) of men and 13(0.5%) of women, p = 0.84.